+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tecovirimat Drugs Market - Global Forecast 2025-2030- Product Image
Tecovirimat Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Tecovirimat Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6138110
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Tecovirimat stands at the forefront of antiviral therapeutics as the first targeted small-molecule treatment for orthopoxvirus infections. Initially developed amid biodefense concerns, its clinical relevance expanded sharply with the resurgence of mpox and renewed preparedness against smallpox. Beyond its mechanism of interfering with viral envelope formation, tecovirimat’s approval pathway underscored the balance between expedited regulatory review and robust safety monitoring. As public health agencies worldwide prioritize antiviral readiness, stakeholders from biopharma innovators to government procurement bodies are aligning on utilization frameworks and stockpiling strategies.

Against this backdrop, the present analysis synthesizes the evolving scientific, regulatory, and commercial drivers that define tecovirimat’s trajectory. It delves into segmentation nuances, tariff implications, and regional performance patterns, offering an integrated perspective designed to inform strategic planning. By illuminating emerging opportunities and potential constraints, this report equips decision-makers with the clarity needed to optimize R&D investments, manufacturing scale-up, and market access initiatives in a dynamic antiviral landscape.

Synergistic convergence of scientific innovation regulatory evolution and collaborative frameworks revolutionizing antiviral development pathways

Advances in drug discovery platforms have accelerated the identification of antiviral candidates with novel mechanisms of action, and tecovirimat exemplifies how structure-based design can yield highly selective inhibitors. Concurrently, regulatory bodies have adopted adaptive pathways, including accelerated approvals and rolling submissions, which have reduced time to market while maintaining rigorous safety and efficacy standards. International harmonization efforts further streamline cross-border access, enabling synchronized clinical development and supply planning.

In parallel, collaborative frameworks between government agencies, academic institutions, and private manufacturers have fostered shared risk models for capacity expansion and distribution logistics. These alliances leverage combined expertise in process optimization, quality assurance, and cold-chain management to mitigate potential bottlenecks. At the same time, digital health technologies-from remote patient monitoring to electronic batch tracking-are enhancing pharmacovigilance and enabling real-time visibility across the supply chain. Consequently, the tecovirimat landscape is transforming through scientific innovation, regulatory evolution, and strategic partnerships that together are reshaping how antiviral therapies are discovered, approved, and delivered.

Navigating the 2025 tariff-driven cost challenges to safeguard competitive supply chains and patient access for antiviral therapeutics

The imposition of new tariffs on active pharmaceutical ingredient imports and critical excipients in 2025 has shifted the cost calculus for tecovirimat manufacturing. Where supply agreements once hinged primarily on volume commitments, producers now face elevated base costs that compress margins or necessitate price adjustments. This environment compels contract development and manufacturing organizations to reassess supplier portfolios, consider domestic API production, and renegotiate long-term commitments to absorb incremental duties.

Moreover, higher landed costs influence tender strategies for government procurement, driving demand for local sourcing incentives and spurring dialogue on tariff exemptions for essential health products. Pricing pressures cascade through distribution channels, affecting hospital formulary decisions and private sector purchasing. In response, forward-looking companies are exploring vertical integration models, co-manufacturing partnerships, and in-house formulation capabilities to shield their cost structures. As tariffs reshape the economics of tecovirimat supply chains, strategic agility will be paramount in maintaining competitive positioning and ensuring uninterrupted patient access.

In-depth segmentation perspective revealing formulation distribution indication and dosing nuances shaping tecovirimat utilization patterns

Based on formulation analysis, injectable, tablet, and topical presentations each play distinct roles in treatment protocols, with injectable versions further differentiated into intramuscular and intravenous options while tablets are divided into film-coated and immediate-release formats. Distribution channel dynamics reveal that government procurement remains a cornerstone of market demand, complemented by hospital pharmacy networks-spanning inpatient and outpatient services-and burgeoning online and retail pharmacies, which include both chain and independent outlets.

Indication segmentation highlights the dual relevance of tecovirimat in managing mpox outbreaks and serving as a strategic countermeasure for smallpox preparedness. End users range from specialized clinics and government agencies to both private and public hospitals as well as research institutes engaged in clinical studies. Treatment stage considerations encompass post-exposure prophylaxis, pre-exposure prophylaxis, and therapeutic use, each influencing dosing regimens aligned with 200 mg twice-daily, 400 mg once- or twice-daily, and 600 mg once- or twice-daily strengths. Understanding these intertwined segmentation factors is critical for designing targeted distribution models, optimizing inventory allocations, and tailoring commercial strategies to distinct patient and institutional needs.

Comparative analysis of regional government procurement regulatory frameworks and manufacturing capabilities shaping tecovirimat adoption trends

Within the Americas, robust government stockpiling initiatives and established manufacturing capabilities underpin sustained demand for tecovirimat, with North American facilities leading supply chain resilience efforts. In Europe, Middle East & Africa, diverse regulatory frameworks and collaborative procurement agreements drive heterogeneous adoption rates, while joint tender mechanisms help streamline cross-border supply for regional health authorities. Regulatory alignment initiatives, such as mutual recognition pathways, are easing market entry across multiple jurisdictions.

Asia-Pacific markets exhibit a mixed landscape, where advanced healthcare systems in countries like Japan and Australia facilitate early adoption, whereas emerging markets in Southeast Asia are prioritizing infrastructure development and local production partnerships. Policymakers in the region are considering tariff reductions and incentive programs to bolster domestic API manufacturing and strengthen pandemic preparedness. Recognizing these regional dynamics enables stakeholders to calibrate market entry strategies, prioritize clinical trial sites, and forge alliances that reflect local regulatory and procurement environments.

Strategic collaborations innovation investments and capacity expansions defining competitive dynamics among key antiviral market players

SIGA Technologies, as the originator of the antiviral compound, continues to lead through strategic collaborations with government agencies and contract manufacturers, ensuring scalable production and supply security. Emerging biotech firms are pursuing next-generation oral formulations and alternative delivery systems in partnership with academic research centers, accelerating pipeline diversification. Meanwhile, global contract development and manufacturing organizations are expanding capacity by investing in specialized facilities designed for small-molecule antiviral synthesis and stringent quality control.

Concurrently, established pharmaceutical multinationals are evaluating in-licensing agreements to broaden their infectious disease portfolios, leveraging existing commercial footprints for rapid market penetration. Supply chain integrators are developing integrated API-to-formulation capabilities to offer end-to-end services, improving cost predictability and lead-time reliability. These varying approaches underscore the competitive interplay between innovation-driven startups, specialized CDO/CDMO providers, and traditional pharma players seeking to consolidate their positions in the lucrative antiviral market.

Actionable strategies for enhancing supply chain resilience regulatory engagement and collaborative innovation in the antiviral sector

Industry leaders should prioritize diversification of API sourcing by establishing partnerships with domestic manufacturers and exploring backward integration to mitigate tariff-induced cost volatility. Early engagement with regulatory authorities is essential to navigate emerging policy changes and secure expedited review pathways. Additionally, investing in patient-centric oral and topical formulations can enhance adherence and broaden use cases beyond hospital settings.

It is also critical to leverage digital platforms for real-time supply chain monitoring, ensuring transparency and rapid response to potential disruptions. Companies should explore co-development agreements with academic institutions to access cutting-edge research while sharing development risk. Moreover, aligning commercial strategies with government pandemic preparedness programs and providing flexible pricing models for strategic stockpiling can strengthen long-term partnerships with health authorities. By acting on these recommendations, organizations can fortify their market positioning and drive sustainable growth in a competitive antiviral landscape.

Rigorous mixed-methods research framework combining secondary data reviews primary stakeholder interviews and methodological triangulation

This analysis integrates comprehensive secondary research, including reviews of peer-reviewed literature, regulatory filings, and publicly available intelligence on antiviral therapeutics. Primary research was conducted through structured interviews with senior executives at pharmaceutical companies, clinical investigators, hospital procurement directors, and government health agency representatives. Data points were validated through triangulation across multiple sources to ensure accuracy and minimize bias.

Market segmentation parameters were defined using a top-down approach, followed by bottom-up validation to align product presentations, distribution channels, indications, end-user segments, treatment stages, and dosage strengths. Regional assessments combined macroeconomic indicators, healthcare infrastructure metrics, and policy environment analyses. Tariff impact evaluation drew upon trade data and regulatory notices governing pharmaceutical imports. Quality control measures included peer reviews by subject-matter experts and cross-functional internal audits to guarantee methodological rigor and reliability of insights.

Integrated review of innovation regulatory commercial and regional factors defining competitive advantage in the tecovirimat market

The tecovirimat landscape is characterized by scientific innovation, regulatory evolution, and dynamic commercial strategies that collectively shape market outcomes. Segment-specific insights into formulation types, distribution channels, indications, end-user preferences, treatment stages, and dosage strengths reveal nuanced adoption patterns. Tariff changes in 2025 introduce cost pressures that demand strategic supply chain adjustments and cost mitigation tactics.

Regional disparities across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlight the importance of tailoring market entry and growth strategies to local regulatory and procurement environments. Key players are deploying diverse business models-from originator partnerships and CDMO expansions to in-licensing and integrated supply solutions-to capture market opportunities. By adhering to the actionable recommendations outlined, organizations can strengthen resilience, optimize regulatory pathways, and capitalize on collaborative innovation, securing their competitive advantage in the evolving antiviral therapeutics arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Formulation
    • Injectable
      • Intramuscular
      • Intravenous
    • Tablet
      • Film Coated Tablet
      • Immediate Release Tablet
    • Topical
  • Distribution Channel
    • Government Procurement
    • Hospital Pharmacy
      • Inpatient
      • Outpatient
    • Online Pharmacy
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • Indication
    • Mpox
    • Smallpox
  • End User
    • Clinic
    • Government Agency
    • Hospital
      • Private Hospital
      • Public Hospital
    • Research Institute
  • Treatment Stage
    • Post Exposure Prophylaxis
    • Pre Exposure Prophylaxis
    • Therapeutic Use
  • Dosage Strength
    • 200mg
      • Twice Daily
    • 400mg
      • Once Daily
      • Twice Daily
    • 600mg
      • Once Daily
      • Twice Daily
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • SIGA Technologies, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of tecovirimat in post-exposure prophylaxis protocols for orthopoxvirus outbreaks
5.2. Impact of expanded regulatory approvals for tecovirimat on global smallpox preparedness strategies
5.3. Increasing integration of tecovirimat combination therapies in advanced antiviral treatment regimens
5.4. Growing investment in domestic tecovirimat manufacturing to strengthen strategic stockpile supply chains
5.5. Emerging clinical trial data evaluating tecovirimat efficacy in treatment of monkeypox complications
5.6. Market dynamics influenced by government procurement contracts and emergency use authorizations for tecovirimat
5.7. Advances in oral formulation research to improve patient compliance and bioavailability of tecovirimat
5.8. Collaboration between biotech startups and government agencies to accelerate tecovirimat production scaling
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tecovirimat Drugs Market, by Formulation
8.1. Introduction
8.2. Injectable
8.2.1. Intramuscular
8.2.2. Intravenous
8.3. Tablet
8.3.1. Film Coated Tablet
8.3.2. Immediate Release Tablet
8.4. Topical
9. Tecovirimat Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Government Procurement
9.3. Hospital Pharmacy
9.3.1. Inpatient
9.3.2. Outpatient
9.4. Online Pharmacy
9.5. Retail Pharmacy
9.5.1. Chain Pharmacy
9.5.2. Independent Pharmacy
10. Tecovirimat Drugs Market, by Indication
10.1. Introduction
10.2. Mpox
10.3. Smallpox
11. Tecovirimat Drugs Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Government Agency
11.4. Hospital
11.4.1. Private Hospital
11.4.2. Public Hospital
11.5. Research Institute
12. Tecovirimat Drugs Market, by Treatment Stage
12.1. Introduction
12.2. Post Exposure Prophylaxis
12.3. Pre Exposure Prophylaxis
12.4. Therapeutic Use
13. Tecovirimat Drugs Market, by Dosage Strength
13.1. Introduction
13.2. 200mg
13.2.1. Twice Daily
13.3. 400mg
13.3.1. Once Daily
13.3.2. Twice Daily
13.4. 600mg
13.4.1. Once Daily
13.4.2. Twice Daily
14. Americas Tecovirimat Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Tecovirimat Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Tecovirimat Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. SIGA Technologies, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TECOVIRIMAT DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. TECOVIRIMAT DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. TECOVIRIMAT DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. TECOVIRIMAT DRUGS MARKET: RESEARCHAI
FIGURE 28. TECOVIRIMAT DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. TECOVIRIMAT DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. TECOVIRIMAT DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TECOVIRIMAT DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY FILM COATED TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY FILM COATED TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY IMMEDIATE RELEASE TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY IMMEDIATE RELEASE TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY GOVERNMENT PROCUREMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY MPOX, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY MPOX, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY SMALLPOX, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY SMALLPOX, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY GOVERNMENT AGENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY GOVERNMENT AGENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TWICE DAILY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TWICE DAILY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY ONCE DAILY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY ONCE DAILY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TWICE DAILY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TWICE DAILY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY ONCE DAILY, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY ONCE DAILY, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TWICE DAILY, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY TWICE DAILY, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES TECOVIRIMAT DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 165. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 167. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 168. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 169. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 170. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 171. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 182. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 183. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 184. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 185. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 186. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 187. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 188. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 189. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 190. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 191. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 192. CANADA TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 193. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 194. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 195. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 196. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 197. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 198. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 199. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 210. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 211. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 212. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 213. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 214. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 215. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 216. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 217. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 218. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 219. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 220. MEXICO TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA TECOVIRIMAT DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 318. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 320. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 324. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 326. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 328. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 329. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2018-2024 (USD MILLION)
TABLE 330. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY 200MG, 2025-2030 (USD MILLION)
TABLE 331. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2018-2024 (USD MILLION)
TABLE 332. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY 400MG, 2025-2030 (USD MILLION)
TABLE 333. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2018-2024 (USD MILLION)
TABLE 334. UNITED KINGDOM TECOVIRIMAT DRUGS MARKET SIZE, BY 600MG, 2025-2030 (USD MILLION)
TABLE 335. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 336. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 337. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 338. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 339. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 340. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 341. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 342. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 343. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 344. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 345. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 346. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 347. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 348. GERMANY TECOVIRIMAT DRUGS MARKET SIZE, BY IN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tecovirimat Drugs market report include:
  • SIGA Technologies, Inc.

Related Topics

Related Reports

Monkeypox - Competitive Landscape, 2024 - Product Image

Monkeypox - Competitive Landscape, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Monkey Pox Treatment Market Report 2025 - Product Image

Monkey Pox Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Smallpox Treatment - Global Strategic Business Report - Product Image

Smallpox Treatment - Global Strategic Business Report

  • Report
  • 250 Pages
  • Global
From
Smallpox Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Smallpox Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Monkeypox Vaccine and Treatment - Global Strategic Business Report - Product Image

Monkeypox Vaccine and Treatment - Global Strategic Business Report

  • Report
  • 455 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.